Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: Potential immunosuppressants in transplantation immunology

Transplantation

Volumn 68, Issue 9, 1999, Pages 1383-1392

  Lai, Jenn Haung ^a   Ho, Ling Jun ^b   Kwan, Chiu Yin ^c   Chang, Deh Ming ^a   Lee, Ta Chung ^d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c MCMASTER UNIVERSITY   (Canada)

^d Army 802 Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID DERIVATIVE; BERBAMINE; DAURICINE; HERNANDESINE; TETRANDRINE;

ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033571497     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199911150-00027     Document Type: Article

References (67)

1. Lafferty KJ, Prowse SJ, Simeonovic CJ. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu Rev Immunol 1983; 1: 143.
2. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233.
3. Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993; 178: 1753.
4. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321.
5. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997; 9: 396.
6. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985.
7. Marengere LEM, Waterhouse P, Duncan GS, Mittrucker HW, Feng G-S, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996; 272: 1170.
8. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996; 184: 783.
9. Wu Y, Guo Y, Huang A, Zheng P, Liu Y. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J Exp Med 1997; 185: 1327.
10. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4lg. Science 1992; 257: 789.
11. Lin H, Boiling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA-4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
12. Azuma H, Chandraker A, Nadeau K, et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996; 93: 12439.
13. Lakkis FG, Konieczny BT, Saleem S, et al. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997; 158: 2443.
14. Onodera K, Chandraker A, Schaub M, et al. CD28-B7 T cell costimulatory blockade by CTLA-4Ig in sensitized rat recipients. J Immunol 1997; 159: 1711.
15. Woodward JE, Bayer AL, Chavin KD, Blue ML, Baliga P. T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade. Transplantation 1998; 66: 14.
16. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101: 2309.
17. Via CS, Rus V, Nguyen P, Linsley P, Gause WC. Differential effect of CTLA-4Ig on murine graft-versus-host disease (GVHD) development: CTLA-4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol 1996; 157: 4258.
18. + T cells. J Immunol 1996; 157: 3250.
19. Li QL, Xu YH, Zhon ZH, et al. The therapeutic effect of tetrandrine on silicosis. Chin J Tuberc Res Dis 1981; 4: 321.
20. Chang HM, But PH. Pharmacology and application of Chinese materia medica, Vol. I and II. Singapore/Philadelphia, PA: World Scientific Publishing, 1987.
21. Tang W, Eisenbrand G. Chinese drugs of plant origin: chemistry, pharmacology, and use in traditional and modern medicine. Berlin, Hedelberg: Springer-Verlag, 1992.
22. 2+ antagonistic action: effects on vascular smooth muscle and adrenal gland. In Vinson GP, Anderson DC, eds. Adrenal glands, vascular system and hypertension. Bristol UK: J Endocrinol Ltd, 1996: 103-114.
23. Lai J-H, Horvath G, Subleski J, Bruder J, Ghosh P, Tan T-H. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol Cell Biol 1995; 15: 4260.
24. Ho L-J, Chang D-M, Chang M-L, Kuo S-Y, Lai J-H. Mechanism of immunosuppression of the antirheumatic herb TWHf in human T cells. J Rheumatol 1999; 26: 14.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55.
26. Seou WK, Ferrante A, Goh DBH, Chambers AH, Li SY, Thong YH. In vitro immunosuppressive properties of the plant alkaloid tetrandrine. Int Arch Allergy Appl Immunol 1988; 85: 410.
27. June CH, Ledbetter JA, Lindsten T, Thompson CB. Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. J Immunol 1989; 143: 153.
28. Ghosh P, Tan TH, Rice NR, Sica A, Young HA. The interleukin 2 CD28-responsive complex contains at least three members of the NF-κB family: c-Rel, p50, and p65. Proc Natl Acad Sci USA 1993; 90: 1696.
29. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145.
30. Croft M, Carter L, Swain SL. Generation of antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1995; 180: 1715.
31. Dey BR, Yang YG, Szot GL, Pearson DA, Sykes M. Interleukin-12 inhibits graft-versus-host disease through a Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood 1998; 91: 3315.
32. Mampaso F, Sanchez-Madrid F, Marcen R, et al. Expression of adhesion molecules in allograft renal dysfunction: a distinct diagnostic pattern in rejection and cyclosporin nephrotoxicity. Transplantation 1993; 56: 687.
33. Dong Y, Yang MMP, Kwan C-Y. In vitro inhibition of proliferation of HL-60 cells by tetrandrine and coriolus versicolor peptide derived from Chinese medicinal herbs. Life Sci 1997; 60: 135.
34. Bryan RG, Li Y, Lai J-H, et al. The effect of CD28 signal transduction on c-Rel in human peripheral blood T cells. Mol Cell Biol 1994; 14: 7933.
35. Lai J-H, Tan T-H. CD28 signaling causes a sustained down-regulation of IκBα which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994; 269: 30077.
36. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal transduction during costimulation of T lymphocytes. Cell 1994; 77: 727.
37. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote survival by enhancing the expression of Bcl-xL. Immunity 1995; 3: 87.
38. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989; 244: 339.
39. Los M, Schenk H, Hexel K, Baeuerle PA, Droge W, Schulze-Osthoff K. IL-2 gene expression and NF-κB activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J 1995; 14: 3731.
40. Ghosh P, Sica A, Cippitelli M, et al. Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway. J Biol Chem 1996; 271: 7700.
41. Hsueh YP, Liang HE, Ng SY, Lai MZ. CD28-costimulation activates cyclic AMP-responsive element-binding protein in T lymphocytes. J Immunol 1997; 158: 85.
42. Teh BS, Seou WK, Chambers AH, Playford S, Ioannoni B, Thong YH. Inhibition of histamine release from rat mast cells by the plant alkaloid tetrandrine. Int Arch Allergy Appl Immunol 1988; 86: 220.
43. Ferrante S, Seou WK, Rowan-Kelly B, Thong YH. Tetrandrine, a plant alkaloid, inhibits the production of tumor necrosis factor-alpha (cachectin) by human monocytes. Clin Exp Immunol 1990; 80: 232.
44. Reist RH, Dey RD, Durham JP, Rojanasakul Y, Casiranova V. Inhibition of proliferative activity of pulmonary fibroblasts by tetrandrine. Toxicol Appl Pharmacol 1993; 122: 70.
45. Miles PR, Bowman L, Ma JKH, Ma JYC. Alterations in alveolar type II cell metabolism induced by tetrandrine and other alkaloids. Toxicol Appl Pharmacol 1993; 119: 142.
46. Whitehouse MW, Fairlie DP, Thong YH. Anti-inflammatory activity of the isoquinoline alkaloid, tetrandrine, against established adjuvant arthritis in rats. Agents Actions 1994; 42: 123.
47. Pang L, Hoult JRS. Cytotoxicity to macrophages of tetrandrine, an antisilicosis alkaloid, companied by an overproduction of prostaglandins. Biochem Pharmacol 1997; 53: 773.
48. Chang D-M, Chang W-Y, Kuo S-Y, Chang M-L. The effects of traditional antirheumatic herbal medicines on immune response cells. J Rheumatol 1997; 24: 436.
49. Ho L-J, Chang D-M, Lee T-C, Chang M-L, Lai J-H. Plant alkaloid tetrandrine downregulates protein kinase C-dependent signaling pathway in T cells. Eur J Pharm 1999; 367/2-3: 389.
50. Teng JMC, Liu X-R, Mills GB, Dupont B. CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C. J Immunol 1996; 156: 3222.
51. Lucey DR, Clerici M, Shearer GM. Type 1 and Type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9: 532.
52. Romagnani S. The TH1/TH2 paradigm. Immunol Today 1997; 18: 263.
53. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in mouse systems: the differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
54. O'Connell PJ, Paul WE. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 1993; 150: 1093.
55. Chen N, Field E. Enhanced type 2 and diminished type 1 cytokines in neonatal tolerance. Transplantation 1995; 59: 933.
56. Nickerson P, Steurer W, Steiger J, Zheng X, Steele AW, Strom TB. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994; 6: 757.
57. Fowler DH, Kurasawa K, Smith R, Eckaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogenic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540.
58. Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL. Polarized type 2 alloreactive CD4 and CD8 donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585.
59. Konieczny BT, Dai Z, Elwood ET, et al. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 1998; 160: 2059.
60. Krieger NR, Most D, Bromberg JS, et al. Coexistence of TH1- and TH2-type cytokine profiles in anti-CD2 monoclonal antibody-induced tolerance. Transplantation 1996; 62: 1285.
61. Thai NL, Fu F, Qian S, et al. Cytokine mRNA profiles in mouse orthotopic liver transplantation. Transplantation 1995; 59: 274.
62. Ruiz P, Nassiri M, Gregorian S, Viciana AL, Streilein JW. Neonatal transplantation tolerance is associated with a systemic reduction in memory cells, altered chimeric cell phenotype, and modified eicosanoid and cytokine production. Transplantation 1996; 61: 1198.
63. Snijdewint FG, Kapsenberg ML, Warben-Penris PJ, Bos JD. Corticosteroids class-dependently inhibit in vitro Th1- and Th2-type cytokine production. Immunopharmacology 1995; 29: 93.
64. Zhou JA, Fang WY, Wang C, Zhou JC, Guan HP. The effects of dauricine and verapamil as calcium channel blockers on the plasma concentration of 6-keto-prostaglandin F1 alpha and thromboxane B2 during cardiopulmonary bypass. Thorac Cardiovasc Surg 1987; 35: 172.
65. Wong CW, Seow WK, O'Callanghan JW, Thong YH. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumor necrosis factor and platelet-activated factor. Agents Actions 1992; 36: 112.
66. Luo CN, Lin X, Li WK, et al. Effect of berbamine on T-cell mediated immunity and the prevention of rejection on skin transplants in mice. J Ethanopharmacol 1998; 59: 211.
67. Hu SM, Xu SM, Yao XS, Lui CB, Tezuka Y, Kikuchi T. Dauricoside, a new glycosidal alkaloid having an inhibitory activity against blood-platelet aggregation. Chem Pharmaceut Bull 1993; 41: 1866.